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Abstract 
Introduction: Apoptotic genes regulate apoptosis by the action of their pro- and antiapoptotic products. Among 
the most important proteins are p53 and Bcl-2 proteins. The rate of tumor growth is dependent on the balance 
between proliferation and apoptosis at all stages of carcinogenesis. The differential expression of these apoptotic 
genes was analyzed in relation to clinicopathological criteria as Gleason Score in man with Prostate Cancer. 
Every prostate cancer patient who underwent histopathology examination which fulfill the criteria were included 
in the study. Samples then rearrange into low Gleason Score (2-6) and high Gleason Score (7-10). All samples 
then underwent gene expression assay for p53 and bcl-2 to be analyzed for each’s relationship with each group. 
The aim of this study was to evaluate tumor proliferation and the expression of the proto-oncogene Bcl-2 and 
tumor suppressor gene p53 in patients undergoing transurethral prostatectomy for prostate cancer, and to define 
their prognostic roles through correlation with final Gleason score, using qRTPCR.. A total of 40 samples 
consisting of 28 GS (2-6) and 12 GS (7-10) samples were included in the study. There was a significant mean 
difference between p53 mRNA in the GS 2-6 and 7-10 groups (p <0.001), but not for bcl-2 mRNA. Based on a 
multivariate analysis, only p53 mRNA had a significant association with the GS group in Adenocarcinoma 
Prostate with p = 0.014, 95% CI 0.926-0.991 with a predicted value of 77.5%. We conclude that p53 mRNA is 
an independent predictive factor of Gleason Score-based progression of adenocarcinoma Prostate. 
Keywords: Prostate cancer; p53; bcl-2; gene expression; gleason score. 
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1. Introduction 
Mutated p53 is one of the most common genetic abnormalities detected in human cancers. As a major tumor 
suppressor gene, p53 regulates the cell cycle, controls DNA repair mechanisms and activates apoptotic 
pathways [1]. The clinical correlates of p53 mutations malignancies have not been fully delineated but have 
shown that p53 mutation accelerates cancer progression and increases tumor invasiveness and metastasis, which 
is not, however, the entire picture [2,3]. Translocation the Bcl-2 oncogene on chromosome 18, giving rise to 
activation of the Bcl-2 gene, with increased production of mRNA and protein [4]. Bcl-2 is an oncogene with 
anti-apoptotic activity. It has been related to androgen independent prostate adenocarcinomas [5]. Proliferative 
activity tends to be low in prostate cancer and higher rates have been related to higher tumor stage and disease-
specific survival [6]. The activity of proliferating cell nuclear antigen has been evaluated in a number of tumors 
and has been related to prognosis [7]. 
The diagnosis of prostatic carcinoma is based on histopathological examination of tissue obtained from the 
prostate gland. A key feature in a histopathological report of cancer is the grading of the aggressiveness. For 
prostatic carcinoma, the most widely used method for this grading was developed by Donald Gleason, and is 
known as the Gleason scoring system [8,9]. The Gleason grading system remains one of the important 
prognostic and predicting factors for prostate carcinoma [10]. More recently, the emergence of molecular 
medicine has resulted in the increased use of techniques able to quantitate levels of RNA in clinical diagnostics  
[11]. Quantitative real-time PCR (qPCR) has become a useful tool for validation and reduction of data produced 
from microarray studies [12,13].  
Many PCa biomarker studies employ microarrays to identify profiles of the disease and its progression 
[14,15,16]. The aim of this study was to evaluate tumor proliferation and the expression of the proto-oncogen 
Bcl-2 and tumor suppressor gene p53 in patients undergoing transurethral prostatectomy for prostate carcinoma, 
and to define their prognostic roles through correlation with final Gleason score, using qRTPCR. 
2. Material and Method 
Forty patients who were treated by transurethral resection of the prostate in 2015 to 2016 for adenocarcinoma 
prostate were analyzed according to histopathological standard methods. Fixation of tissue sample using normal 
buffer formalin 10%. Tissue preparation from FFPE as previous describe [17]. Total RNA extraction using 
QIAsymphony instrument with the RNeasyÒFFPE Kit (Qiagen) following the instructions suggested by the 
manufacturer. Reverse transcription and quantitative real-time polymerase chain reaction (QRTPCR) in one step 
using Rotor Gen Q (Qiagen) perform by adding 2µl total RNA to Master Mix (Qiagen) (15 µl) consisting of the 
following components: 5.0 µl of 5 reaction buffer, 0.5 µl of dNTP, 0.1 µl of M-MLV reverse transcriptase, 
(Moloney Murine Leukemia Virus reverse transcriptase; 200 U/µl; USB), and 9.4 µl of dH2O. 10 µl of 
SYBRTMGreen (Qiagen), 1.5 l of each primer (see table 1). The housekeeping genes like GAPDH should be 
used as controls for normalization (see table 1). Running amplification as described previously [18]. Analysis 
procedures supported by Rotor-Gene Q software. 
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Table 1: The primer used for reverse transcription 
Gen Primer 
p53 F5’GAG CTG AAT GAG GCC TTGG A3’ 
R : 5’CTG AGT CAG GCC CTT CCG TCT T3’ 
bcl-2 F : 5’TTG TGG CCT TCT TTG AGT TCG GTG3’ 
R  :  5’GGT GCC GGT TCA GGT ACT CAG 
TCA3’ 
GAPGH F : 5’TGA TGA CAT CAA GAA GGT GGT GAA3’ 
R : 5’TTC TTG GAG GCC ATG TGG GCC AT3’ 
 
3. Result 
In 40 sample divided into two groups, low Gleason score (2-6) is 28 (70%) and high Gleason score (7-10) is 
12(30%). Median age in low Gleason score is 70 years and high Gleason score is 67.5 years. Median PSA 
before TURP in low Gs is 12,15 ng% and high Gleason score is 12,05 ng%. Most of clinical staging tumor is 
T1c. Mean of mRNA Bcl-2 expression in low Gleason score is 80.34 ± 117.60 and in high Gleason score is 
31.01 ± 23.48.  
Bivariate analysis mRNA Bcl-2 correlate not significant to Gleason score although the trend is rising in high 
Gleason score. Mean of mRNA P53 expression in low Gleason score is 243.52 ± 490.52 and in high Gleason 
score is 20.47 ± 24.08. Bivariate analysis of mRNA P53 and Gleason score refer to significant correlation (p 
value < 0,001).  
Table 2: Sample Characteristic 
 Group 
Variable GS 2-6 
N=28 
GS 7-10 
N=12 
Age  
Median 
Min-Max 
PSA 
Median 
Min-max 
Tumor 
T1c 
T2a 
T2b 
T2c 
T3a 
T4 
 
70 
60-82 
 
12.15 
4.5-100 
 
13 (46.4%) 
2  (7.1%) 
5 (55.6%) 
5 (17.9%) 
0 (0%) 
3 (10.7%) 
 
67.5 
57-78 
 
12.05 
5.4-76.4 
 
6 (50%) 
1 (8.3%) 
4 33.3%) 
0 (0%) 
1 (8.3%) 
0 (0%) 
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Table 3: Bivariate analysis between mRNA p53 and low GS (2-6) and high GS (7-10) 
 Group  
Variable                  GS 2-6      GS 7-10 P Value 
 N=28        N=12  
mRNA p53 243.52 ± 490.52 20.47 ± 24.08 <0.001* 
 
Multivariate analysis mRNA Bcl-2 and mRNAP53 result only P53 has significant correlation to Gleason score 
(p value < 0,014).  
Table 4: Multivariate analysis mRNA P53, Bcl-2 and Gleason score 
 B S.E. Wald df Sig.     Exp(B) 95% C.I.for EXP(B) 
Lower Upper 
Step 1a 
Age -0.017 0.088 0.037 1 0.847 0.983 0.828 1.167 
mRNAp53 -0.038 0.018 4.214 1 0.040 0.963 0.929 0.998 
mRNABcl2 -0.007 0.008 0.836 1 0.361 0.993 0.977 1.008 
Constant 2.454 5.970 0.169 1 0.681 11.631   
Step 2a 
mRNAp53 -0.039 0.018 4.697 1 0.030 0.962 0.929 0.996 
mRNABcl2 -0.007 0.008 0.807 1 0.369 0.993 0.977 1.009 
Constant 1.310 0.715 3.354 1 0.067 3.705   
Step 3a 
mRNAp53 -0.043 0.017 6.027 1 0.014 0.958 0.926 0.991 
Constant 1.098 0.651 2.841 1 0.092 2.997   
          
 
4. Discussion 
PCa is one of the malignancies with the highest frequency of genetic variations [19]. Renan has calculated a 
probability of 12 mutated genes from epidemiological data [20]. It has been suggested that a subset of mutant 
alleles acquired by a sub clone of tumor cells early in tumorigenesis leads not only to a selected replication 
advantage, but also, later in tumorigenesis, to the ability to metastasize [21]. Clinical tumor stage, Gleason 
score, and pretherapy serum prostate-specific antigen (PSA) in descending order were independently associated 
with clinical or biochemical relapse of PCa [22]. mRNA P53 expression is an absolute value result from 
transcription promoter gen P53. It has been suggested that a subset of mutation and the protein caused apoptosis 
not function, cell survival and DNA repaired not occurred. The cancer cell become progressive and prognosis is 
worse, cancer undergo metastasis and castration resistant. Although not only apoptosis has a role, perhaps there 
is multiple mutation follow the first mutation [23,24]. The antiapoptotic protein Bcl-2 is overexpressed in about 
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half of all prostate cancers, particularly in androgen-independent cases [25]. Second factor in diminished 
apoptosis in prostate cancers is Bcl-2. Bcl-2 is not expressed in normal secretory epithelial cells of the prostate, 
but starting from PIN, Bcl-2 is frequently expressed throughout the epithelium [25]. Interestingly, in the 
androgen-dependent LNCaP prostate carcinoma cell line Bcl-2 expression is androgen-dependent [26]. 
TP53 tumor suppressor gene is one of the most frequently mutated genes in human malignancies [27]. However, 
the mutation frequency of TP53 in PCa has a low level of about 30% [28]. Furthermore, the TP53 mutation 
frequency in prostate tumor tissue does not show a significant rising level in correlation with rising tumor 
grading and staging, as for example in bladder cancer. Mutations of TP53 influence the activation of cell 
proliferation and suppression of DNA repair, and apoptosis [29]. Therefore, an acceleration of tumor 
progression by TP53 mutations was claimed [30,31]. Kuczyk and his colleagues have described a correlation 
between overexpression of p53 protein and tumor progression in PCa patients during univariate analysis. P53 
overexpression, histological grading, and tumor stage were significant prognostic factors for survival, among 
which only P53 overexpression remained an independent significant predictor in multivariate analysis [32]. 
In this study gen P53 expression, histopathological Gleason score during univariate and multivariate analysis 
were significant correlated.  
5. Limitations 
Although the research has reached its aims, there were some unavoidable limitations. First, because of the time 
limit, this research was conducted only on a small size of population who underwent TURP surgery. As 
mentioned before, the median age was 70 years old. And on that age, the amount of patient who were medically 
eligible for the TURP operation was considerably low. Another challenge faced was the level of education each 
patient had. In terms of understanding, the majority of our patients were below average. Therefore, their 
misguided concern about patient’s safety discouraged our patients and their relatives to be enlisted in the 
experiment.  
6. Conclusion 
It was found that P53 gene expression was significantly correlated with the progression of prostate cancer. 
7. Recommendation 
With that result, P53 gene expression can be used as an independent prognostic factor for prostate cancer.  
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